Epitope base editing: Non-malignant stem cells are going undercover

Shayan Saniei; Elvin Wagenblast

doi:10.1016/j.stem.2023.09.009

Epitope base editing: Non-malignant stem cells are going undercover

Shayan Saniei
, Elvin Wagenblast

Research output: Contribution to journal › Comment/debate

Abstract

Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.

Original language	English
Pages (from-to)	1400-1402
Number of pages	3
Journal	Cell Stem Cell
Volume	30
Issue number	11
DOIs	https://doi.org/10.1016/j.stem.2023.09.009
State	Published - 2 Nov 2023

Access to Document

10.1016/j.stem.2023.09.009

Cite this

@article{e3bc7a298b3f426483670400fae14d4e,

title = "Epitope base editing: Non-malignant stem cells are going undercover",

abstract = "Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.",

author = "Shayan Saniei and Elvin Wagenblast",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = nov,

day = "2",

doi = "10.1016/j.stem.2023.09.009",

language = "English",

volume = "30",

pages = "1400--1402",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Epitope base editing

T2 - Non-malignant stem cells are going undercover

AU - Saniei, Shayan

AU - Wagenblast, Elvin

PY - 2023/11/2

Y1 - 2023/11/2

N2 - Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.

AB - Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.

UR - https://www.scopus.com/pages/publications/85174971838

U2 - 10.1016/j.stem.2023.09.009

DO - 10.1016/j.stem.2023.09.009

M3 - Comment/debate

C2 - 37922877

AN - SCOPUS:85174971838

SN - 1934-5909

VL - 30

SP - 1400

EP - 1402

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 11

ER -

Epitope base editing: Non-malignant stem cells are going undercover

Abstract

Access to Document

Fingerprint

Cite this